• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Goldman initiated coverage on ResMed

    1/16/25 7:53:14 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care
    Get the next $RMD alert in real time by email
    Goldman initiated coverage of ResMed with a rating of Buy
    Get the next $RMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RMD

    DatePrice TargetRatingAnalyst
    3/19/2025$280.00Overweight
    Morgan Stanley
    3/19/2025Overweight
    Morgan Stanley
    1/16/2025Buy
    Goldman
    1/10/2025$252.00Neutral
    Piper Sandler
    12/13/2024$250.00Hold
    Stifel
    9/24/2024$280.00Outperform
    Robert W. Baird
    9/18/2024$180.00Peer Perform → Underperform
    Wolfe Research
    9/4/2024Buy → Hold
    Needham
    More analyst ratings

    $RMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Resmed Names Salli Schwartz as Chief Investor Relations Officer

      SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

      4/21/25 5:00:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Jan De Witte joins GHO Capital as Operating Partner

      Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

      2/11/25 4:30:00 AM ET
      $IART
      $RMD
      Medical/Dental Instruments
      Health Care
    • Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

      NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's

      2/4/25 9:15:00 AM ET
      $IXHL
      $RMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments

    $RMD
    SEC Filings

    See more
    • SEC Form 144 filed by ResMed Inc.

      144 - RESMED INC (0000943819) (Subject)

      5/7/25 8:12:48 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by ResMed Inc.

      8-K - RESMED INC (0000943819) (Filer)

      4/23/25 4:05:31 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by ResMed Inc.

      144 - RESMED INC (0000943819) (Subject)

      2/5/25 6:57:52 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Resmed Acquires VirtuOx

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed's commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx's at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected wa

      5/1/25 9:00:00 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025

      Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%Operating cash flow of $579 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended March 31, 2025. Third Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 8% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 140 bps to 59.3%; non-GAAP gross margin improved 140 bps to 59.9%Income from operations increased 14%; non-GAAP income from operations up 13

      4/23/25 4:05:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Resmed Names Salli Schwartz as Chief Investor Relations Officer

      SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

      4/21/25 5:00:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $RMD
    Financials

    Live finance-specific insights

    See more
    • Resmed Acquires VirtuOx

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed's commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx's at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected wa

      5/1/25 9:00:00 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025

      Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%Operating cash flow of $579 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended March 31, 2025. Third Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 8% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 140 bps to 59.3%; non-GAAP gross margin improved 140 bps to 59.9%Income from operations increased 14%; non-GAAP income from operations up 13

      4/23/25 4:05:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025

      SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location:https://investor.resmed.com •Date:Wednesday, April 23, 2025 •Time:1:30 p.m. PDT / 4:30 p.m. EDT •International:London, Wednesday, April 23, 2025, 9:30 p.m. BST   Sydney, Thursday, April 24, 2025, 6:30 a.m. AEST Please note,

      4/2/25 4:05:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

      SC 13G/A - RESMED INC (0000943819) (Subject)

      2/10/23 1:36:52 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

      SC 13G/A - RESMED INC (0000943819) (Subject)

      2/10/22 5:05:17 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

      SC 13G/A - RESMED INC (0000943819) (Subject)

      2/10/22 8:32:59 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Farrell Peter C sold $484,500 worth of ResMed Common Stock (2,000 units at $242.25), decreasing direct ownership by 3% to 71,218 units (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      5/8/25 5:38:05 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Sandercock Brett sold $215,580 worth of ResMed Common Stock (1,000 units at $215.58), decreasing direct ownership by 1% to 89,864 units (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      4/10/25 6:14:32 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Farrell Michael J. exercised 8,009 units of ResMed Common Stock at a strike of $101.64 and sold $1,680,699 worth of ResMed Common Stock (8,009 units at $209.85), decreasing direct ownership by 0.00% to 455,472 units (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      4/9/25 10:52:15 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on ResMed with a new price target

      Morgan Stanley initiated coverage of ResMed with a rating of Overweight and set a new price target of $280.00

      3/19/25 10:13:23 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley initiated coverage on ResMed

      Morgan Stanley initiated coverage of ResMed with a rating of Overweight

      3/19/25 8:18:03 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on ResMed

      Goldman initiated coverage of ResMed with a rating of Buy

      1/16/25 7:53:14 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care